Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.40 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.40 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CA3 | P07451 | 1/20 | 0.37 |
| ▸ | CA4 | P22748 | 1/20 | 0.37 |
| ▸ | CA6 | P23280 | 1/20 | 0.37 |
| ▸ | CA5A | P35218 | 1/20 | 0.37 |
| ▸ | CA7 | P43166 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7603154 | 0.98 | PIK3CD (0.49) | PIK3CDKMT2AMEN1PKML3MBTL1 | |
| SCHEMBL7604655 | 0.98 | PIK3CD (0.49) | PIK3CDKMT2AMEN1PKML3MBTL1 | |
| SCHEMBL3761334 | 0.98 | PIK3CD (0.47) | PIK3CDKMT2AMEN1PKML3MBTL1 | |
| SCHEMBL7603177 | 0.97 | PIK3CD (0.50) | PIK3CDKMT2AMEN1PKML3MBTL1 | |
| SCHEMBL7607553 | 0.97 | PIK3CD (0.50) | PIK3CDKMT2AMEN1PKML3MBTL1 | |
| SCHEMBL1705435 | 0.93 | PIK3CD (0.53) | PIK3CDKMT2AMEN1PKMCHRM2 | |
| SCHEMBL9787818 | 0.88 | PIK3CD (0.44) | PIK3CDKMT2AMEN1PKML3MBTL1 | |
| SCHEMBL22105254 | 0.85 | CHRM2 (0.48) | PIK3CDKMT2ACHRM2CHRM4CHRM5 | |
| SCHEMBL7603739 | 0.84 | KMT2A (0.39) | PIK3CDKMT2AMEN1PKML3MBTL1 | |
| SCHEMBL7603856 | 0.84 | CHRM2 (0.35) | PIK3CDKMT2AMEN1PKMCHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240240106-A1 | 1,4-BUTANEDIOL MONO- OR DIESTERS FOR USE AS AROMA CHEMICALS | BASF SE (DE) | 2024-07-18 | — | — | US | claimed |
| EP-4347756-A1 | 1,4-BUTANEDIOL MONO- OR DIESTERS FOR USE AS AROMA CHEMICALS | BASF SE (DE) | 2024-04-10 | — | — | EP | claimed |
| US-9594073-B2 | Test solvent for evaluating the compatibility of biologically active substances and graft copolymers | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2017-03-14 | — | — | US | claimed |
| US-20130118238-A1 | TEST SOLVENT FOR EVALUATING THE COMPATIBILITY OF BIOLOGICALLY ACTIVE SUBSTANCES AND GRAFT COPOLYMERS | ABBOTT GMBH & CO. KG (DE) | 2013-05-16 | — | — | US | claimed |
| US-6497886-B1 | SOLVENTS FOR PHARMACEUTICAL PREPARATIONS WHICH, BESIDES EXCELLENT DISSOLVING CAPACITY FOR ACTIVE INGREDIENT USED, ALSO PROVIDE EXCELLENT MISCIBILITY WITH OTHER SOLVENTS AND GOOD PHYSIOLOGICAL TOLERABILITY | BASF AKTIENGESELLSCHAFT (DE) | 2002-12-24 | — | — | US | claimed |
| EP-0934080-B1 | 1,3-BIS-(N-LACTAMYL) PROPANE AND THE PHARMACEUTICAL AND COSMETIC USE THEREOF | BASF AG (DE) | 2002-06-12 | — | — | EP | claimed |
| US-20250195409-A1 | METHODS FOR IMPROVING CUTANEOUS PERMEATION OF CANNABINOIDS AND FATTY ACID AMIDES | Ananda Scientific, Inc. (US) | 2025-06-19 | — | — | US | disclosed |
| US-20240240106-A1 | 1,4-BUTANEDIOL MONO- OR DIESTERS FOR USE AS AROMA CHEMICALS | BASF SE (DE) | 2024-07-18 | — | — | US | disclosed |
| EP-4347756-A1 | 1,4-BUTANEDIOL MONO- OR DIESTERS FOR USE AS AROMA CHEMICALS | BASF SE (DE) | 2024-04-10 | — | — | EP | disclosed |
| US-9594073-B2 | Test solvent for evaluating the compatibility of biologically active substances and graft copolymers | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2017-03-14 | — | — | US | disclosed |
| US-9594073-B2 | Test solvent for evaluating the compatibility of biologically active substances and graft copolymers | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2017-03-14 | — | — | US | disclosed |
| US-20130118238-A1 | TEST SOLVENT FOR EVALUATING THE COMPATIBILITY OF BIOLOGICALLY ACTIVE SUBSTANCES AND GRAFT COPOLYMERS | ABBOTT GMBH & CO. KG (DE) | 2013-05-16 | — | — | US | disclosed |
| US-20130118238-A1 | TEST SOLVENT FOR EVALUATING THE COMPATIBILITY OF BIOLOGICALLY ACTIVE SUBSTANCES AND GRAFT COPOLYMERS | ABBOTT GMBH & CO. KG (DE) | 2013-05-16 | — | — | US | disclosed |
| US-20100297223-A1 | PHARMACEUTICAL DOSAGE FORM COMPRISING A LIQUID OR FLOWABLE CORE COMPOSITION | ABBOTT GMBH & CO. KG (DE) | 2010-11-25 | — | — | US | disclosed |
| US-20090220596-A1 | Composition and Dosage Form Comprising a Solid or Semi-Solid Matrix | ABBOTT GMBH & CO. KG (DE) | 2009-09-03 | — | — | US | disclosed |
| EP-2072044-A1 | Pharmaceutical dosage form comprising a liquid or flowable core composition | Abbott GmbH & Co. KG (DE) | 2009-06-24 | — | — | EP | disclosed |
| US-6497886-B1 | SOLVENTS FOR PHARMACEUTICAL PREPARATIONS WHICH, BESIDES EXCELLENT DISSOLVING CAPACITY FOR ACTIVE INGREDIENT USED, ALSO PROVIDE EXCELLENT MISCIBILITY WITH OTHER SOLVENTS AND GOOD PHYSIOLOGICAL TOLERABILITY | BASF AKTIENGESELLSCHAFT (DE) | 2002-12-24 | — | — | US | disclosed |
| EP-0934080-B1 | 1,3-BIS-(N-LACTAMYL) PROPANE AND THE PHARMACEUTICAL AND COSMETIC USE THEREOF | BASF AG (DE) | 2002-06-12 | — | — | EP | disclosed |
| EP-0934080-A2 | 1,3-BIS-(N-LACTAMYL) PROPANE AND THE PHARMACEUTICAL AND COSMETIC USE THEREOF | BASF AKTIENGESELLSCHAFT (DE) | 1999-08-11 | — | — | EP | disclosed |
| WO-1998015291-A1 | 1,3-BIS-(N-LACTAMYL) PROPANE AND THE PHARMACEUTICAL AND COSMETIC USE THEREOF | BASF AKTIENGESELLSCHAFT (DE) | 1998-04-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090220596-A1 | Composition and Dosage Form Comprising a Solid or Semi-Solid Matrix | SBDS, PBRM1, COL1A1 | PIK3CD 2784/4885KMT2A 2539/4885MEN1 342/4885 |
| US-20250195409-A1 | METHODS FOR IMPROVING CUTANEOUS PERMEATION OF CANNABINOIDS AND FATTY ACID AMIDES | CNR2, CNR1, FAAH | PIK3CD 1664/4885KMT2A 2718/4885MEN1 4840/4885 |
| US-20100297223-A1 | PHARMACEUTICAL DOSAGE FORM COMPRISING A LIQUID OR FLOWABLE CORE COMPOSITION | F7, OSTC, PWWP2B | PIK3CD 2263/4885KMT2A 4555/4885MEN1 1058/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.